My Cart Find A Store

Drug

Mitoxantrone

Pronounced

"my-toe-ZAN-trone"

Uses

Mitoxantrone is used to treat leukemia and other cancers. It is also used to treat multiple sclerosis. It belongs to a class of drugs known as anthracenediones and works by slowing or stopping the growth of certain cells (including cancer cells and cells that affect the body's natural defenses).

Warning

Mitoxantrone must be given only by injection into a vein. Do not give by injection into a muscle, under the skin, or into the spinal cord. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage. Tell your doctor right away if you notice redness, pain, or swelling at or near the injection site.

This medication may rarely cause serious (rarely fatal) heart problems (including heart failure). This effect may occur during treatment or months to years after treatment is completed. The risk of heart problems is affected by your dose, medical history (including previous heart disease, radiation treatment to the chest area, or if you have MS-multiple sclerosis), and previous use of this and other drugs (including doxorubicin or daunorubicin). Tell your doctor right away if you notice symptoms such as irregular heartbeat, shortness of breath, swelling ankles/feet, unusual tiredness, or unusual/sudden weight gain.

Very rarely, people who are treated with this type of medication have developed new cancers (such as secondary leukemia). The risk may be increased when this medication is given with certain anti-cancer drugs or radiation treatment. Consult your doctor for more details.

Lab and/or medical tests (such as complete blood count, heart/liver function tests, ECG) should be done before you start treatment with this medication and while you are using it. Keep all medical and lab appointments. Consult your doctor for more details.

How to Use This Medication

Read the Medication Guide provided by your pharmacist before you start receiving mitoxantrone and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection into a vein by a health care professional as directed by your doctor. The dosage is based on your medical condition, body size, and response to treatment.

If this medication touches your skin, immediately wash the area well with soap and water. If this medication gets in your eye, open the eyelid and flush with water for 15 minutes, then get medical help right away.

Copyright © 2025 TraceGains, Inc. All rights reserved.

RxAnswers™ is a copyrighted combined product from TraceGains and First DataBank, Inc.

Drug information is selected from data included with permission and copyrighted by First DataBank, Inc. This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional. Always seek the advice of your healthcare professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your healthcare professional. This information does not contain any assurances that this product is safe, effective or appropriate for you.

This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.

Learn more about First DataBank

There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer

Learn more about TraceGains, the company.

TraceGains and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.

Information expires December 2025.